HEART NEWS AND VIEWS

The News Bulletin of the International Society for Heart Research

www.ishrworld.org Volume 9, Number 1, 2001

Past Truth & Present Poetry



15. Amateurs in Science, Charles A. Lindbergh

AMATEURS are those fortunate men and women who enjoy working in fields not connected with their professional occupation. Most amateurs interested in intellectual pursuits are found in the arts, such as literature and music. Their reward is the pleasure derived from their voluntary occupation. Because science is based on thorough education, quantitative observation and on long years of professional training, amateurs are rare in the sciences as compared to the arts.

Charles A. Lindbergh, the pilot, well known for his solo flight from New York to Paris in 1927, is an example of an amateur working in biological science. I chose Lindbergh as an example because I knew him well and worked with him in 1936 when I was a young M.D. and a fellow at the Rockefeller Institute, now the Rockefeller University, in New York City with Dr Alexis Carrel, the well known experimental surgeon and Nobelist. Lindbergh had no experience in the biological sciences but had ingenious ideas when it came to solution of technical problems. He became interested in medical science because he tried to find a cure for his sister-in-law, Elizabeth Morrow who had severe mitral stenosis. Why, he reasoned, would it not be possible to construct a mechanical device capable of circulating blood through parts of the body, bypassing the heart, leaving it bloodless and accessible to the surgeon. Therefore, what he had in mind was essentially a heart-lung bypass. It was not until the 1950's that Gibbon in Philadelphia, after long animal experimentation, built and used the first heart-lung bypass system on a patient with congenital heart disease.

Therefore Lindbergh, the amateur, was far ahead of his time when in 1929 he conceived the idea of a cardio-pulmonary bypass! He consulted his wife's physician, an anesthesiologist, who referred him to Dr Alexis Carrel. As an amateur, Lindbergh did not foresee the difficulties inherent in such a project. In contrast, Carrel, a professional, discouraged Lindbergh's idea because he was aware of the difficulties in preventing blood clotting and maintaining sterility. Instead, Carrel suggested that Lindbergh design an apparatus which would perfuse the whole organ under sterile conditions. This would permit the study of the effect of the environment (the perfusion fluid) on isolated organs. Lindbergh's technical approach was ingenious, such as the use of floating glass valves and an air driven pump which permitted variations in systolic and diastolic perfusion pressure and pulse rate. I remember Lindbergh's frequent use of "airplane dope", as he called it, a solution which sealed glass and rubber tubing and which he previously employed on his airplane. Despite the ingenious device, the culture of whole organs never found universal use. As compared to today's molecular biological methods, Lindbergh and Carrel's perfusion system was primitive; its main value is historical, based on the two great men who designed it. But I believe that there still is a future for the culture of whole organs, primarily in the field of virology.

Lindbergh was an amateur in science; he was motivated by his enthusiasm for new ventures leading from his troubled present (the kidnapping of his child) to a more romantic future in the field of science. This enthusiasm of amateurs is a gift which they bring to science and to art. Their approach is "amateurish", unbiased, fresh and enthusiastic, qualities which professionals have sometimes lost in the daily grind of professional work; but their ideas may open the door to new and original approaches in science and in art.

Lindbergh's dedication to biological science is well illustrated in the following letter to me, part of which is presented here.

Switzerland
Dec. 12, 1970

Dear Richard,

I thoroughly enjoyed my visit with you at Pasadena

— seeing your research projects, inspecting the hospital, meeting your associates, the pleasant hour at your home, etc. You were most considerate to drive me back to the airport that night.

How time collapses under the circumstances of our visit — the thirty years between Carrel's laboratory and your own. There are moments when it seems to me that the time-gap disappears without the separation that we think so obvious in death. Maybe if man had deeper awareness, life and death would make less difference. I am inclined to think so.

Again, thanks for your hospitality and friendship. I hope your experimental projects meet with the utmost success.

Best wishes to you always,

Charles

Charles A. Lindbergh

Richard J. Bing, M.D. ■

Composition of the ISHR Council for 2001 - 2004

The election for five vacant seats on Council has been completed and the newly-elected members are: Metin Avkiran (UK), Gerd Hasenfuss (Germany), Eduardo Marbán (USA), Tom Hintze (USA), and Elizabeth Murphy (USA).

The following persons are currently serving on Council and will continue to serve for another three years: Giuseppe Ambrosio (Italy), Masao Endoh (Japan), Masayasu Hiraoka (Japan), Litsa Kranias (USA), Michael Schneider (USA), Nobuakira Takeda (Japan), and Peter McLennan (Australia).

In order to facilitate communication between the International Section and the individual Sections, Council has recently established that each ISHR Section will have one or two statutory members in the International Council. The following individuals have been chosen by the Sections to serve as their statutory members: Indian Section: N.K. Ganguly (President); North American Section: Keith Reimer (President), William Weglicki (Secretary); European Section: Jean-Jacques Mercadier (President), Ketty Schwartz (Past President); Japanese Section: Yoshio Yazaki (President), Akira Takeshita; Latin American Section: Otoni Moreira Gomes (President); Australasian Section: Lindsay Brown (President); Chinese Section: Chide Han. (In 2002, the statutory members for the European Section will be Gerd Heusch [President] and Jean-Jacques Mercadier [Past President]).

In addition, Jim Downey (President), Roberto Ferrari (President-Elect), David Hearse (Past President), Roberto Bolli (Secretary General), Richard Walsh (Editor of *JMCC*), and Tom Ruigrok (Editor of *HN&V*) will be Council Members.

Thus, the composition of the new Council is the following:

Giuseppe Ambrosio (Italy)
Metin Avkiran (UK)
Roberto Bolli (USA)
LindsayBrown (Australia)
Jim Downey (USA)
Masao Endoh (Japan)
Roberto Ferrari (Italy)
N.K. Ganguly (India)
Otoni Moreira Gomes (Brazil)
Chide Han (China)
Gerd Hasenfuss (Germany)
David Hearse (UK)
Tom Hintze (USA)
Masayasu Hiraoka (Japan)
Litsa Kranias (USA)
Eduardo Marbán (USA)
Peter McLennan (Australia)
Jean-Jacques Mercadier (France)
Elizabeth Murphy (USA)
Keith Reimer (USA)
Tom Ruigrok (The Netherlands)
Michael Schneider (USA)
Ketty Schwartz (France)
Nobuakira Takeda (Japan)
Akira Takeshita (Japan)
Richard Walsh (USA)
William Weglicki (USA)
Yoshio Yazaki (Japan)

Roberto Bolli, M.D.
Secretary General, ISHR ■

PRESIDENT'S VALEDICTORY LETTER

Having been a member of our Society since 1973 and a member of our Council since 1979, I have seen our Society evolve from the very small 'International Study Group for Research in Cardiac Metabolism' to a fully fledged, large international organisation that now embraces not only metabolism but all research disciplines. In 1998, as incoming President, I had a number of hopes for our Society and it is now timely to review these and any changes which have occurred.

The Journal of Molecular and Cellular Cardiology

Thanks to the concerted efforts and commitment of a succession of excellent Editors, our official publication has become a successful and highly respected journal, the impact factor and publication efficiency of which continues to improve. The ISHR does not own the Journal but it has always benefited by receiving a small percentage of the publisher's profits. My first challenge as President was to renegotiate our contract with the publishers and fortunately we managed to agree a number of improvements relating to the Journal and its running, plus a new financial agreement that increased our income by over fourfold. This additional income should help the Society develop a number of important initiatives in the coming years.

Fellowship of the ISHR

In 1998, I proposed to our Council that the ISHR, like other major societies, should recognise the outstanding achievements of some of its members by conferring Fellowships. Council supported this scheme strongly and it's pleasing to report that the first group of 82 Founding Fellows of the ISHR have now been identified and the scheme is fully operational. I would like to acknowledge the great help Dr Howard Morgan who, as Chairman of the Fellowship Credentials Committee, ensured that the selection of Fellows from a very large number of nominations was rigorous and fair. The Fellowship scheme is a three-yearly event and the next group of Fellows will be announced in time for our World Congress in Brisbane in 2004. As evidenced by this issue of HEART NEWS AND VIEWS, a biosketch of each new Fellow will be published in our bulletin.

Structure of our Society

For a very long time and for understandable reasons, our Society has occasionally suffered from a lack of co-ordination and communication between its constituent Sections. This has resulted in unfavourable clashes of Section meeting dates, difficulties in establishing a complete and up-to-date world membership and a number of other problems. To begin to address this, Council has agreed to restructure its composition by replacing a number of elected positions with statutory positions occupied by one or more representatives of each of our Sections.

The running of our Society

When appointed as Secretary General in 1989, my highest priority was to enhance the way in which the ISHR functioned, endeavouring to establish: *(i)* a world membership list, *(ii)* guidelines for a variety of procedures, *(iii)* an active Finance Committee to improve the financial affairs of the Society, *(iv)* Travel Awards for Young Investigators, *(v)* a regular news bulletin (HEART NEWS AND VIEWS), *(vi)* a unified image for the Society and *(vii)* a fundraising drive with the long term hope that one day the ISHR might be able to establish a permanent office. Whilst much was achieved, a great deal remains to be done and it is very pleasing to record that Roberto Bolli, our current Secretary General, is energetically continuing this quest and is making enormous improvements in the image and functioning of the ISHR.

Awards

In addition to the initiation of the ISHR Fellowship Programme, the past three years has witnessed the establishment of a new major award: the Research Achievement Award. This Award is aimed at recognising outstanding research and also providing a bridge between the Richard Bing Young Investigators' Award and the

Peter Harris Senior Investigators' Award. Great credit must be given to Roberto Bolli for conceiving this Award and for making it possible by securing the generous support of Chugai Pharmaceuticals. The Award carries with it a prize of $30,000 and the first awardee will be Dr Eduardo Marban. I have no doubt that this new Award will do much to enhance the status of the ISHR.

Web site

In 1998, I urged our Council to establish a really effective web site. Thanks to the skills and creativity of Jim Downey and the help and support of Roberto Bolli, the Society now has a superb and ever-growing site with links to all of our Sections, a host of important information (including features such as H.E.L.P.) and an ever-improving membership list. The site also features highlights of outstanding Section meetings, such as that held in Louisville in 2000.

Academic links

The ISHR has always been open to links with other societies and organisations (usually at a Section level) but in the past three years we have formalised a link, at the international level, with the American Heart Association Council on Basic Cardiovascular Science. We have cross representation on our respective Councils and play a part in formulating each other's scientific programmes. This represents a very important opportunity for the ISHR and thanks must go to Roberto Bolli, Jim Downey and Rick Walsh for their work in realising this important connection. Opportunities exist for more links with other major societies (such as the European Society of Cardiology) and, hopefully, future Councils will seize such opportunities. In this connection, it is pleasing that in 2004 our Congress in Brisbane will be held jointly with the Cardiac Society of Australia and New Zealand.

World Congresses

In 1998, Brisbane won the competition to host our 2004 World Congress and, this year in Winnipeg, there will be three excellent bids (Italy, Israel and Latin America) for our 2007 Congress. The result will be announced at our Members Meeting but before that our thanks should go to each of the proposers for expressing their willingness to host such a major event.

Heart News and Views and Membership benefits

Our Bulletin, under the very capable editorship of Tom Ruigrok (shortly to be joined by Colin Bloor as Deputy-Editor), has become a regular and valuable means of communication for our Society. Sponsored initially by Bayer and more recently by Servier, this membership benefit provides an excellent means of communication with our members. In 1998, the Council agreed there was a need to identify and increase membership benefits and this aim is now being fulfilled through: *(i)* markedly reduced registration rates for our members at World Congresses (Greece, Winnipeg and Brisbane), *(ii)* a proper membership certificate (currently being sent to all members), *(iii)* a massive discount on the personal subscription rate for the *Journal of Molecular and Cellular Cardiology*, *(iv)* the services of our website and *(v)* receipt of HEART NEWS AND VIEWS. However, in the future more will be done, including the production of a membership pack for new members.

Council and Officers

Finally, I would like to take this opportunity to thank the 1998-2001 Council for the support and help that it has provided to me. In particular, I would like to thank Roberto Bolli who, as a good friend and Secretary General, has done so much to help in the achievement of the above goals. I would like to wish him and our new President Jim Downey, together with the new Council (see elsewhere in this issue of HEART NEWS AND VIEWS) every success in continuing to build the International Society for Heart Research.

It has been an enjoyable privilege to have served the Society for so many years - especially since the ISHR and its meetings, in addition to enhancing my scientific life, has provided me with so many wonderful and lasting international friendships.

David J. Hearse

Spotlight on our Sponsors

Since 1999, the publication of HEART NEWS AND VIEWS is made possible by the generous support of Servier. This article features the main activities of Servier: the search for new molecules and the development of their therapeutic applications, as well as the Company's involvement in medical education.

Dr Jacques Servier

Who are Servier?

Servier is the first private French pharmaceutical company with a turnover of 11.6 billion FRF (1.7 billion USD) and employing 13,600 people.

As the third French pharmaceutical company worldwide, Servier is present in 140 countries with 75% of sales in units at the international level.

Servier devotes 25% of its turnover to Research and Development *(R&D)* and has research centers in most of the European countries as well as in Latin America (based in Rio de Janeiro), China, and Australia.

What are their Products?

Servier's *R&D* has discovered products in five key areas: metabolic diseases, CNS diseases, cancer, bone diseases and menopause, as well as cardiovascular diseases.

In the cardiovascular area, Servier is marketing:

- Natrilix SR (Indapamide), a diuretic specifically designed for treating hypertension, the first of its class in terms of patients treated worldwide. Indapamide is the drug regimen used in Hyvet (**HY**pertension in the **V**ery **E**lderly **T**rial) a large morbi-mortality trial to evaluate the outcome of treating hypertension in the very elderly. Results are expected in 2008.
- Hyperium (Rilmenidine), a molecule binding specifically to I_1 receptors thus providing a physiological control of blood pressure
- Coversyl (Perindopril), an ACE inhibitor indicated in hypertension and heart failure with a 24h blood pressure control and reduced-risk of first dose hypotension. Coversyl is the drug regimen chosen in:
  - PROGRESS (**P**erindopril p**RO**tection a**G**ainst **RE**current **S**troke **S**tudy), a 6,000-patient study to define the reduction of stroke recurrence in patients with a history of cerebro-vascular disease. Results will be announced at the 11th Congress of the European Society for Hypertension (Milan, Italy; June 15-19, 2001).
  - EUROPA (**EU**ropean trial on **R**eduction **O**f cardiac events with **P**erindopril in stable coronary **A**rtery disease), a 10,000-patient study to define the reduction of cardiovascular events in patients with stable angina. Results should be known in 2002.
- Preterax (Perindopril 2 mg, Indapamide 0.625 mg) is a very-low dose combination indicated first-line in hypertension. It has been chosen for ADVANCE (**A**ction in **D**iabetes and **V**ascular disease: preter**A**x and di-amicro**N** **C**ontrol **E**valuation) a 10,000 diabetic normo- and hypertensive-patient trial designed to study the effect of lowering blood pressure on cardiovascular events.
- Vastarel (Trimetazidine) is a metabolic agent indicated in stable angina. By inhibiting 3-ketoacyl CoA thiolase (3-KAT), Vastarel shifts energy metabolism from β-oxidation to glucose metabolism, thus protecting the myocardial cell against ischemia.

Research at Servier

How did Servier Originate?

Dr Jacques Servier started the company in 1954 in Orleans, south of Paris. Both a pharmacist and a medical doctor, he is the President and owner of the

Servier Company which grew from nine people at its start to 13,600 today. The company is headquartered in Neuilly Sur Seine, near Paris but has retained its roots in the Loire Valley, with two research centers in Orleans and a manufacturing plant in Gidy. The company's motto, "Life through discovery", illustrates the philosophy of Dr Servier:

- research of new drugs satisfying both patients and doctors needs;
- employees developing harmoniously their career with the company.

What about Research?

From its inception, Servier has always devoted a large share of its turnover to *R&D*: 25% as compared to 12% on average for the pharmaceutical industry. In the past 30 years, such investment has allowed the company to synthesize 35,000 molecules with 8,000 patented worldwide.

High-level researchers have been attracted to work with Servier due to its philosophy and dynamism. Chemists, pharmacologists and clinicians are working very closely allowing continuity from research to development. Teams are dedicated to a specific therapeutic area allowing for focused research.

Servier is also well known for its strategic alliances with academic research. By designing these partnerships, Servier contributes to medical progress while benefiting from advanced technologies to discover new drugs.

Research is headed by Prof. Paul Vanhoutte, the distinguished vascular biologist. With his strong interest and expertise in vascular biology, it is not surprising that the company is focusing upon this important target.

In particular, Servier is developing a selective and specific If-current inhibitor which exclusively reduces heart rate. Ivabradine is currently in phase III development for stable angina and a European registration will be filed in 2002.

Other drugs are in development in the cardiovascular field:

- antihypertensive,
- antithrombotic,
- phlebotropic.

Servier's manufacturing plant in Gidy (France)

Servier's Commitment to Education

Servier is strongly committed to medical education in many fields, in particular in diabetes and depression.

In the cardiology field, Servier is also very active, witness the sponsorship of HEART NEWS AND VIEWS. It sponsors a number of major books and publications including *Dialogues in Cardiovascular Medicine*, edited by Roberto Ferrari and David J. Hearse, a new journal which has been adopted by the European Society of Cardiology (ESC) as part of its programme of continuing medical education.

Servier also sponsors the Education and training programme of ESC and has created together with the European Section of the ISHR, the ISHR-ES / SERVIER Research Fellowship. It will be awarded for the first time during the XVII World Congress of the ISHR in Winnipeg to a young researcher in Cardiology to allow him or her a research work in a European laboratory, supported by a grant of 20,000 Euro.

For more information, visit their website at **www.servier.com**.

Tom J.C. Ruigrok, Ph.D.
Utrecht, The Netherlands ■

Founding Fellows of the International Society for Heart Research

THE MISSION of the International Society for Heart Research is to promote research that advances our understanding of cardiovascular disease and helps to develop new therapeutic strategies. In line with this, the ISHR has recently established a Fellowship status as a means of recognizing those members who have distinguished themselves for outstanding contributions to cardiovascular research. A total of eighty-two Founding Fellows of the ISHR have been selected by a Credentials Committee chaired by Dr Howard Morgan. ISHR members were nominated either by the Council of the ISHR or by one of its Sections or by the Editorial Board of the *Journal of Molecular and Cellular Cardiology*, and their credentials reviewed by the members of the Committee. To ensure that only the highest caliber scientists would be bestowed this distinction, the number of Founding Fellows has been limited to a small fraction of our membership of thousands, using stringent selection criteria.

FELLOWS were selected solely on the basis of scientific excellence, as evidenced by an established track record of publications in high-impact journals. The main criterion in assigning Fellowship status was the performance of independent research that has made a major contribution to advancing our understanding of cardiovascular biology and medicine. Political considerations or service contributions to the ISHR were not a factor in the selection.

THE EIGHTY-TWO FOUNDING FELLOWS will be introduced at the XVIIth World Congress of the ISHR in Winnipeg in July 2001. Additional Fellows will be appointed every three years as determined by the Selection Committee, and introduced at future World Congresses. The eventual total number of Fellows will not exceed 5% of the membership of the Society.

BENEFITS of ISHR Fellowship include free registration at the ISHR World Congresses and a complimentary (hard copy) subscription to the *Journal of Molecular and Cellular Cardiology*, the official journal of our Society. A brief biosketch of each Fellow will be published in HEART NEWS AND VIEWS, the official News Bulletin of the ISHR, and a Fellowship Certificate will be provided to each Fellow. Fellows also receive a complimentary subscription to *Dialogues in Cardiovascular Medicine*.

THE ESTABLISHMENT of a Fellowship underscores the commitment of the ISHR to recognize and foster excellence in research. The Society looks to its Fellows for leadership and guidance in its various activities, particularly organization of conferences, selection of awardees, and dissemination of knowledge. We are proud of the contributions that our Founding Fellows have made to cardiovascular biology and medicine and look forward to working with them towards our goal of promoting the scientific mission of the ISHR.

Roberto Bolli, M.D.
Secretary General, ISHR

David J. Hearse, Ph.D., D.Sc.
President, ISHR

The Founding Fellows of the ISHR

Norman **ALPERT**	Burlington, VT, USA
Piero **ANVERSA**	Valhalla, NY, USA
Donald **BERS**	Maywood, IL, USA
Richard J. **BING**	Pasadena, CA, USA
Roberto **BOLLI**	Louisville, KY, USA
Maximilian **BUJA**	Houston, TX, USA
Edward **CARMELIET**	Blanden, Belgium
Britton **CHANCE**	Philadelphia, PA, USA
Naranjan S. **DHALLA**	Winnipeg, Man, Canada
James M. **DOWNEY**	Mobile, AL, USA
David A. **EISNER**	Manchester, UK
Masao **ENDOH**	Yamagata, Japan
Roberto **FERRARI**	Ferrara, Italy
Loren J. **FIELD**	Indianapolis, IN, USA
Harry A. **FOZZARD**	Chicago, IL, USA
Colin **GIBBS**	Clayton, Vic, Australia
Garrett J. **GROSS**	Milwaukee, WI, USA
William **GROSSMAN**	San Francisco, CA, USA
David J. **HEARSE**	London, UK
Gerd **HEUSCH**	Essen, Germany
Joanne S. **INGWALL**	Boston, MA, USA
Seigo **IZUMO**	Boston, MA, USA
Michael J. **JANSE**	Amsterdam, Netherlands
Robert B. **JENNINGS**	Durham, NC, USA
Arnold M. **KATZ**	Norwich, VT, USA
Francis J. **KLOCKE**	Chicago, IL, USA
Evangelia (Litsa) **KRANIAS**	Cincinnati, OH, USA
Edward G. **LAKATTA**	Baltimore, MD, USA
Glenn A. **LANGER**	Little River, CA, USA
W. Jonathan **LEDERER**	Baltimore, MD, USA
Robert J. **LEFKOWITZ**	Durham, NC, USA
Jeffrey M. **LEIDEN**	Abbot Park, IL, USA
Leslie **LEINWAND**	Boulder, CO, USA
Peter **LIBBY**	Boston, MA, USA
Benedict **LUCCHESI**	Ann Arbor, MI, USA
David H. **MACLENNAN**	Toronto, Ont, Canada
Eduardo **MARBÁN**	Baltimore, MD, USA
Daria **MOCHLY-ROSEN**	Stanford, CA, USA
Antoon F.M. **MOORMAN**	Amsterdam, Netherlands
Martin **MORAD**	Washington, DC, USA
Howard E. **MORGAN**	Winfield, PA, USA
Richard L. **MOSS**	Madison, WI, USA
Makoto **NAGANO**	Tokyo, Japan
Denis **NOBLE**	Oxford, UK
Eric N. **OLSON**	Dallas, TX, USA
Shunzo **ONISHI**	Osaka, Japan
Lionel H. **OPIE**	Capetown, South Africa
James R. **PARRATT**	Glasgow, UK
Kenneth D. **PHILIPSON**	Los Angeles, CA, USA
Philip A. **POOLE-WILSON**	London, UK
George K. **RADDA**	London, UK
Keith **REIMER**	Durham, NC, USA
Jeffrey **ROBBINS**	Cincinnati, OH, USA
Robert **ROBERTS**	Houston, TX, USA
Michael R. **ROSEN**	New York, NY, USA
Shigetake **SASAYAMA**	Kyoto, Japan
Jutta **SCHAPER**	Bad Nauheim, Germany
Wolfgang **SCHAPER**	Bad Nauheim, Germany
Michael D. **SCHNEIDER**	Houston, TX, USA
Hasso **SCHOLZ**	Hamburg,Germany
Ketty **SCHWARTZ**	Paris, France
Christine **SEIDMAN**	Boston, MA, USA
Jonathan **SEIDMAN**	Boston, MA, USA
Paul **SIMPSON**	San Francisco, CA, USA
R. John **SOLARO**	Chicago, IL, USA
Edmund H. **SONNENBLICK**	Bronx, NY, USA
Hiroyuki **SUGA**	Osaka, Japan
Peter H. **SUGDEN**	London, UK
Bernard **SWYNGHEDAUW**	Paris, France
Laszlo **SZEKERES**	Szeged, Hungary
Michihiko **TADA**	Osaka, Japan
Richard W. **TSIEN**	Stanford, CA, USA
Guy **VASSORT**	Montpellier, France
Dorothy E. **VATNER**	Hackensack, NJ, USA
Stephen F. **VATNER**	Newark, NJ, USA
Richard A. **WALSH**	Cleveland, OH, USA
W. Gil **WIER**	Baltimore, MD, USA
James T. **WILLERSON**	Houston, TX, USA
Saul **WINEGRAD**	Philadelphia, PA, USA
Yoshio **YAZAKI**	Tokyo, Japan
Derek M. **YELLON**	London, UK
Heinz-Gerd **ZIMMER**	Leipzig, Germany

In this issue of HEART NEWS AND VIEWS we start publishing brief biosketches of the eighty-two Founding Fellows of the International Society for Heart Research

The Editors

Robert B Jennings

ISHR member since founding. Member of ISHR Council from 1974 to 1983. President ISHR 1978-1980.
Current post: James B. Duke Professor of Pathology, Duke University Medical Center, Durham, NC.
Training: BS, MS, MD, Northwestern University.
Research interests: Acute myocardial ischemic injury, effect of reperfusion of ischemic myocardium, cause of myocyte death in acute ischemia.
Major research contributions: Definition of reversible and irreversible ischemic injury and contraction band necrosis; Ca^{2+} loading and cell death; wavefront of ischemic cell death; described phenomenon of preconditioning with ischemia together with Charles E. Murry and Keith A. Reimer.
Publications: Three books and over 250 papers.
Most cited paper: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986; **74:** 1124-1136.
Most admired scientist: Albert L. Lehninger.
Relaxation: Golf, gardening, fishing, skiing, learning history, travel.

James R Parratt

Too old to remember when I joined the ISHR! Former member European Section Council.
Present position: Professor Emeritus, Department of Physiology & Pharmacology, Strathclyde Institute for Biomedical Sciences, Glasgow.
Qualifications: PhD, DSc, DSc(Med), MDhc, FRSE, FRCPath, FESC, FISHR.
Main research interests: Sepsis and endotoxaemia; myocardial ischaemia and presently, early post-ischaemia arrhythmias, preconditioning and the cardioprotective effects of exercise.
Spent eight years in the 50's and 60's teaching physiology in Nigeria, then as research fellow in the hyperbaric unit of the Western Infirmary's Department of Surgery in Glasgow. Professor at Strathclyde University since 1976.
For past twelve years have worked with Agnes Vegh, Laszlo Szekeres and Gyula Papp in the Albert Szent-Györgyi Medical School in Szeged, Hungary and have a 'permanent, honorary' appointment there. Two Hungarian grandchildren!
Studied theology (Cambridge Diploma) as well as physiology.
Other major interests (passions): music, piano playing, Hungarian vintage wine and the Scottish Islands.

Michiel J Janse

Current position: Emeritus Professor of Experimental Cardiology. Editor-in-Chief Cardiovascular Research.
Training: University of Amsterdam; State University of New York Downstate Medical Center.
Qualifications: MD, PhD, FESC, FISHR, FRCP(Hon).
Research emphasis: Cardiac electrophysiology and arrhythmias.
Major research contribution: Studies on the electrophysiology of the atrioventricular node, which, together with work of others, notably Gordon K Moe and Carlos Mendez, paved the way for surgery and catheter ablation for AV nodal reentrant tachycardias; mechanisms of arrhythmias caused by ischemia and infarction.
Publications: 195 peer reviewed articles; 98 book chapters; co-editor of 7 books; (co-)author of 3 books.
Most cited article: Flow of "injury" current and patterns of excitation during early ventricular arrhythmias in acute regional ischemia in isolated porcine and canine hearts. Evidence for two different arrhythmogenic mechanisms. *Circ Res* 1980; **47:** 151-163.
Most admired scientist: George Ralph Mines.
Relaxation: Piano playing (classical music); playing soccer; skiing.

David J Hearse

ISHR member since 1973. Member of ISHR Council since 1979. Secretary General ISHR 1989-1995. President ISHR 1998-2001.
Current post: Professor and Director of Cardiovascular Research, The Rayne Institute, St Thomas' Hospital and King's College, London, UK.
Trained: University of Wales, New York University Medical Centre and Imperial College.
Qualifications: BSc, PhD, DSc, FESC, FISHR, FRCP (Hon).
Research emphasis: Mechanisms and manipulation of myocardial injury during ischemia and reperfusion.
Major research contribution: The development of the St Thomas' Hospital Cardioplegic Solution which became, world-wide, the most widely used protective solution during cardiac surgery and transplantation.
Publications: Ten books and over 500 refereed papers.
Science Citation Index most cited paper: The oxygen paradox and the calcium paradox: two facets of the same problem? *J Mol Cell Cardiol* 1978; **10:** 641-68.
Most admired scientist: Albert Szent-Györgyi.
Relaxation: Wood working, house restoration and going to New Zealand.
Favorite dish: Parmigiana di melanzane; *wine:* Puligny-Montrachet; *composer:* Frederick Delius; *painter:* Sidney Schreiber; *author:* John Steinbeck.

Glenn A Langer

ISHR member since 1973.
Current positions: Emeritus Professor of Medicine/Physiology, Emeritus Director of the Cardiovascular Research Laboratory, Emeritus Castera Professor of Cardiology – UCLA School of Medicine. Director, Partnership Scholars Program, an all-volunteer pre-college education program for disadvantaged children.
Training: BA, Colgate Univ.; MD, Columbia Univ.
Research emphasis: The control of myocardial contractility. The subcellular regulation of Ca compartmentation and flux.
Major research contributions: Definition of subcellular origins of calcium flux; calcium in the diadic cleft and the role of inner leaflet sarcolemmal calcium binding in the regulation of sodium-calcium exchange; modeling of intracellular calcium movement during the excitation-contraction cycle.
Publications: Four texts; 200 research papers.
Representative publications: A discrete Na-Ca exchange - dependent Ca compartment in rat ventricular cells: exchange and localization. *Am J Physiol* 1992; **262:** C1149-53; Calcium concentration and movement in the diadic cleft space of the cardiac ventricular cell. *Biophys J* 1996; **70:** 1169-82.
Most admired scientist: Alex Fabiato.
Relaxation: Reading historical non-fiction; golf; walking the California Mendocino Coast; writing.

David A Eisner

Current post: British Heart Foundation Professor of Cardiac Physiology, The University of Manchester, Manchester U.K.
Career: Undergraduate in Cambridge; Postgraduate in Oxford (supervisor Denis Noble); then worked at Univ. Coll. London and the Univ. of Liverpool before moving to Manchester in 1999.
Research: Regulation of intracellular Na and Ca in cardiac muscle and the effects on contractility. Initial work included the role of Na-Ca exchange in mediating the effects of Na pump activity on contraction and showed that contraction is a very steep function of intracellular [Na]. The effects of prolonged changes of membrane potential on Ca were shown to depend on a voltage-dependent Na-Ca exchange and modified by concomitant changes of Na. Subsequent work studied the relative importance of the sarcoplasmic reticulum (SR) and surface membrane in removing Ca from the cell and provided the first direct measurements of SR Ca content. More recent work has focussed on Ca regulation and, in particular, the control of SR Ca content and Ca release. Studies have also been performed on the effects of metabolic inhibition on intracellular Ca regulation. I also have an interest in smooth muscle carried out with my wife Sue (Wray).
Relaxation: Eating, drinking, gardening (growing asparagus in particular).

Roberto Bolli



ISHR member since 1984. Secretary General ISHR 1998-present.
Position: Chief, Division of Cardiology; Director, Institute of Molecular Cardiology, University of Louisville, Louisville, KY.
Training: NIH and Baylor College of Medicine.
Societies: ASCI ('91-); AAP ('99-).
Research interests: Myocardial ischemia/reperfusion injury; gene therapy.
Summary of research work: Our work focused initially on the role of oxygen radicals in myocardial stunning and more recently on the molecular mechanisms underlying the late phase of preconditioning (P), with emphasis on the effectors of P (iNOS, COX-2, aldose reductase), on the ability of NO to induce late P, and on the related signal transduction pathways. Extensive research has also been performed on the cardioprotective effects of gene therapy with NOS isoforms (eNOS, iNOS) and antioxidant enzymes (Ec-SOD).
Publications: Over 200 refereed articles.
Most cited article: Mechanism of myocardial "stunning." *Circulation* 1990; **82:** 723-38 (610 citations).
Positions in scientific organizations: Cardiovasc. and Renal NIH Study Section, '92-'96; Res. Comm. of the AHA, '98-'00; Vice Chairman, AHA Council on Basic Cardiovasc. Sciences, '01-'03; NHLBI Program Project Review Committee, 2000-.

ISHR MEETINGS CALENDAR

■ July 6-11,2001. **XVII World Congress of the International Society for Heart Research.** Winnipeg, Manitoba, Canada. **Enquiries:** XVII ISHR World Congress, c/o Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, University of Manitoba, Faculty of Medicine, 351 Taché Avenue, Winnipeg, Manitoba, Canada R2H 2A6. *Tel.* +1 204 235 3421; *Fax* +1 204 233 6723; *E-mail* ishr@cc.umanitoba.ca; *Website* www.heartconference.com

■ July 2-5, 2001. **Regulation of Energy Metabolism in the Heart and Vasculature.** Banff, Canada. **Enquiries:** Dr G.D. Lopaschuk, c/o Cardiovascular Disease Research Group, Department of Pediatrics, University of Alberta, 423 Heritage Medical Research Centre, Edmonton, AB, Canada T6G 2S2. *Tel.* +1 403 492 2170; *Fax* +1 403 492 9753; *E-mail* gary.lopaschuk@ualberta.ca

■ July 3-5, 2001. **Heart Failure Summit.** Toronto, Canada. **Enquiries:** Dr M.J. Sole, c/o The Centre for Cardiovascular Research, Eaton Wing 13 North - Suite 208, Toronto General Hospital, Toronto, ON, Canada M5G 2C4. *Tel.* +1 416 340 3471; *Fax* +1 416 340 5985; *E-mail* msole@torhosp.toronto.on.ca

■ July 12-15, 2001. **Diseases of the Cardiovascular System and Immunity: Interactions and Therapeutics.** Montreal, Canada. **Enquiries:** Dr G. Bkaily, c/o Department of Anatomy and Cell Biology, Faculty of Medicine, University of Sherbrooke, 3001 12E Avenue North, Sherbrooke, PQ, Canada J1H 5N4. *Tel.* +1 819 564 5303; *Fax* +1 819 564 5320; *E-mail* g.bkaily@courrier.usherb.ca

■ July 12-15, 2001. **Remodeling and Progression of Heart Failure.** Minneapolis, USA. **Enquiries:** Dr I. Anand, c/o Department of Cardiology, VA Medical Center 111C, 1 Veterans Drive, Minneapolis, MN, USA 55417. *Tel.* +1 612 725 2000, ext. 3723; *Fax* +1 612 725 2262; *E-mail* anand001@maroon.tc.umn.edu

■ July 13-17, 2001. **International Muscle Energetics Conference.** Burlington, USA. **Enquiries:** Dr N.R. Alpert, c/o Department of Physiology & Biophysics, University of Vermont, College of Medicine, Given Medical Building, Burlington, VT, USA 05405-0068. *Tel.* +1 802 656 2540; *Fax* +1 802 656 0747; *E-mail* alpert@salus.med.uvm.edu

■ September 2-4, 2001. **Models in Cardiovascular Research (Australasian Section) - Satellite Meeting of the IUPS 2001 Congress.** Brisbane, Australia. **Enquiries:** Conference Secretariat IUPS Satellite Meeting, PO Box 164, Fortitude Valley QLD 4006, Australia. *Tel.* +61 7 3854 1611; *Fax* +61 7 3854 1507; *E-mail* iups@ozaccom.com.au; *Website* www.baker.edu.au/ISHR

■ July 3-6, 2002. **XXII Meeting of the European Section.** Szeged, Hungary. **Enquiries:** Dr A. Végh, Department of Pharmacology and Pharmacotherapy, University of Szeged, Faculty of Medicine, Dóm tér 12, H-6720, Szeged, Hungary. *Tel.* +36 62 545 673; *Fax* +36 62 544 565; *E-mail* vegh@freemail.hu; *Website* www.cardiovasc.com/ishr2002

■ August 7-11, 2004. **XVIII World Congress of the International Society for Heart Research.** Brisbane, Australia. **Enquiries:** ISHR 2004 Congress, PO Box 164, Fortitude Valley QLD 4006, Australia. *Tel.* +61 7 3854 1611; *Fax* +61 7 3854 1507; *E-mail* heart2004@ozaccom.com.au; *Website* www.baker.edu.au/ISHR

In Blue: XVII World Congress and Satellite Meetings

Report from the Israeli Subsection

Between Angiogenesis and Heart Failure: 30 Years of Dedicated Research (April 29 - May 2, 2001; Caesarea, Israel) was the title of a 3-day Symposium organized by the Israeli Subsection of the ISHR-ES as homage to Professors Wolfgang Schaper and Jutta Schaper, of the Experimental Cardiology Department at the Max-Planck Institute in Bad-Nauheim, Germany. Both have collaborated with Israeli researchers for many years and are sincere supporters of the Israeli Subsection.

It has been thirty years since Wolfgang demonstrated the active growth of collateral blood vessels in ischemic heart tissue, heralding the inception of a new discipline in cardiovascular research. Jutta has a place of honor among those who have transformed microscopy from a descriptive to a dynamic science in which the organization of cell components can be related to function and malfunction.

The Symposium dealt with angiogenic and arteriogenic factors, development and adaptation, vascular dysfunction, cardioprotective mechanisms, features of the failing heart and prospects of gene therapy and tissue engineering. The participants, including students, colleagues, disciples or friends of Jutta and Wolfgang, all contributed greatly to the meeting's high scientific level and to the warm, friendly atmosphere.

Gania Kessler-Icekson, Ph.D. and Arié Pinson, D.Sc.
Petach-Tikva and Jerusalem, Israel ■

HEART NEWS AND VIEWS

HEART NEWS AND VIEWS is the official News Bulletin of the International Society for Heart Research and is published every fourth month.

Editorial Office
Markt 13
3961 BC Wijk bij Duurstede
The Netherlands.
Tel.: +31 343 597 555
Fax: +31 343 597 510
E-mail: t.j.c.ruigrok@xs4all.nl